医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

DxTerity’s REDI-Dx Wins 2013 NCT CBRNe Product of the Year Award

2013年12月21日 AM12:25
このエントリーをはてなブックマークに追加


 

LOS ANGELES

DxTerity Diagnostics announced that REDI-Dx™, the company’s blood-based gene expression test for estimating individualized levels of radiation exposure,* was named the 2013 NCT CBRNe Product of the Year. The award was presented at the NCT CBRNe (Non-Conventional Threat Chemical Biological Radiological Nuclear explosion) Asia conference in Kuala Lumpur, Malaysia. REDI-Dx was unanimously selected by the contest jury because “it has a clear end-user benefit, economic efficiency and an excellent match between requirements and the offered solution,” according to Ilja Bonsen, founder and Managing Director of IB Consultancy, an independent defense and security firm specializing in non-conventional threats. “Against the background of mass scale incidents like Fukushima, it permits fast analysis and treatment of victims on the basis of low-cost testing,” according to several members of the award committee.

REDI-Dx is a molecular test designed to estimate an individual’s level of radiation exposure by measuring the relative expression of a panel of radiation-sensitive genes in a blood sample that is collected by either fingerstick or venipuncture. The test represents a significant advance in coordinating an organized response to a nuclear incident by providing emergency responders with rapid, patient-specific information about levels of absorbed ionizing radiation. REDI-Dx was developed as part of an ongoing collaboration between DxTerity Diagnostics and Duke University Medical Center, with funding from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA).

According to Bob Terbrueggen, CEO of DxTerity Diagnostics, “We are excited to receive this award. It recognizes the importance of providing emergency responders with simple biodosimetry tools for testing individuals following a mass scale nuclear incident.”

About DxTerity

DxTerity is a molecular diagnostic company and clinical laboratory based in Rancho Dominguez, CA, that is making genomic testing a routine part of medical care. DxTerity has developed the DxDirect genomic platform that enables simple, fast, and affordable measurement of genomic biomarkers from a single drop of blood.

DxTerity, DxDirect, and REDI-Dx are registered trademarks of DxTerity Diagnostics, Inc.

*REDI-Dx is for Research Use Only. Not for use in diagnostic procedures.

CONTACT

DxTerity Diagnostics Inc.
Phillip Chu, 310-537-7857
info@dxterity.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 武田在日本和爱尔兰的制药工厂荣获2021年度设施类别奖
  • VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China
  • 武田薬品、EGFRエクソン20挿入変異を伴う転移性非小細胞肺がんの治療薬モボセルチニブ(TAK-788)の新薬承認申請を米国FDAが優先審査に指定と発表
  • Dr. Reddy’s Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market
  • Nanotronics Health Donates Hundreds of Non-Invasive Ventilators for COVID-19 Relief in India, in Collaboration with Transworld Group